Company: WHWK
Filing Date: 2025-01-31
Form Type: DEFM14A
Source: 0001193125-25-018470
Chunk: 127

Company: Whitehawk Therapeutics, Inc.
Filing Date: 2025-01-31
Form: DEFM14A
Chunk 127
---
 presentation to Aadi’s board of directors regarding the Divestiture Agreement and any              
 adjustments with respect thereto (to the extent that Kaken requests to make such a presentation); it being understood and agreed that, if, in light of any adjustments to the terms and conditions of the Divestiture Agreement and the transaction   
 documents proposed by Kaken during such period, Aadi’s board of directors does not reaffirm its determinations that (A) such acquisition proposal constitutes a Superior Proposal, and (B) the failure to make an Aadi Board                          
 Recommendation Change in response to such acquisition proposal could reasonably be expected to be inconsistent with its fiduciary duties, then Aadi’s board of directors shall not be permitted to proceed with such Aadi Board Recommendation        
 Change or such termination of the Divestiture Agreement.                                                                                                                                                                                              |

If, at the end of such Notice Period, if, in light of any adjustments to the terms and conditions of the Divestiture Agreement and the transaction documents proposed by Kaken, Aadi’s board of directors cannot or does not reaffirm its determinations that (1) such acquisition proposal constitutes a Superior Proposal, and (2) the failure to make an Aadi Board Recommendation Change in response to such revised, amended, updated or supplemented acquisition proposal could reasonably be expected to be inconsistent with its fiduciary duties, then Aadi’s board of directors shall not be permitted to proceed with such Aadi Board Recommendation Change or such termination of the Divestiture Agreement. Special Meeting Aadi has agreed to take all action necessary in accordance with applicable law, its certificate of incorporation and its bylaws to establish a record date for, duly call, give notice of, convene and hold a meeting of Aadi’s - 85 -

stockholders as promptly as reasonably practicable following the mailing or other dissemination of this proxy statement to Aadi stockholders, at which meeting Aadi has agreed to submit to the
Aadi stockholders the approval of the Divestiture Agreement and the Divestiture. Under the terms of the Divestiture Agreement and subject to certain limitations set forth therein, Aadi is permitted to postpone or adjourn the Special Meeting in
certain circumstances related to soliciting additional proxies or requirements of applicable law.

Anti-Takeover Laws

Aadi and Kaken have agreed not to take any action that would cause any “takeover” law to become applicable to the Divestiture Agreement or the
Divestiture, to take all actions within their power to ensure that no “